Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis

BACKGROUND: Nonalcoholic steatohepatitis (NASH) is characterized by inflammation and hepatocellular damage caused by accumulation of fat in the liver. Resmetirom (MGL-3196) is an orally administered, small-molecule, liver-targeted, selective thyroid hormone receptor-β agonist. This early analysis ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Javanbakht, Mehdi, Fishman, Jesse, Moloney, Eoin, Rydqvist, Peter, Ansaripour, Amir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929016/
https://www.ncbi.nlm.nih.gov/pubmed/36104546
http://dx.doi.org/10.1007/s41669-022-00370-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929016/
https://www.ncbi.nlm.nih.gov/pubmed/36104546
http://dx.doi.org/10.1007/s41669-022-00370-2

Ejemplares similares